Novavax Smashes Q1 2026 Revenue Expectations with Big Vaccine Tech Deals
Novavax beat forecasts with $140M revenue, boosted by vaccine tech deals, new partnerships, and strong cash position.
/ 1656 items
#XY↓
CVS Health Raises 2026 Guidance After Strong Q1 Beat and Better Cost Controls
CVS had strong Q1: revenue $100.4B, earnings beat expectations, raised outlook, cash flow up. Stock rose.
Novo Nordisk Raises Full-Year Guidance After Strong Wegovy Pill Launch
Novo Nordisk beat expectations as its new weight-loss pill sold fast, boosting sales, prescriptions, and improving its 2026 outlook.
Tempus AI Q1 2026: Revenue Beats Expectations, But Stock Drops on Wider Losses
Tempus AI revenue rose 36% to $348M, but losses widened. Stock fell ~7% after weaker profit and cautious outlook.
Avalo Therapeutics Reports Strong Phase 2 Results for Abdakibart in Hidradenitis Suppurativa – Ready to Advance to Phase 3
Avalo’s abdakibart showed strong results in reducing HS symptoms in a Phase 2 trial, with a favorable safety profile and better outcomes than placebo.
Wedbush Ignites Pyxis Oncology with Bullish Rating — 215% Upside Ahead?
Wedbush rates Pyxis “Outperform” with $6 target vs $1.90. Early cancer drug data promising but risky biotech with funding needs.